Clinical Trial Update: Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis [Phase 3]

View source ↗

Summary

Phase 3 safety trial evaluating whether intranasal ciclesonide affects the hypothalamic-pituitary-adrenal axis in children aged 6-11 with perennial allergic rhi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Perennial Allergic Rhinitis

Drugs mentioned

• Ciclesonide nasal aerosol (ciclesonide)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Perennial Allergic Rhinitis, PAR | Phase 3 | Status: COMPLETED | Results posted: 2014-05-26